Advanced Hormone‑Receptor Positive, HER2‑Negative Breast Cancer
The site focuses on neoplasm research, particularly on metastatic HR‑positive, HER2‑negative breast cancer, evaluating new treatment strategies to improve survival and quality of life.
- Comprehensive analysis of ribociclib efficacy and resistance mechanisms
- Evaluation of CDK4/6 inhibitor discontinuation after prolonged disease control
- Assessment of progression‑free and overall survival outcomes at 12 months
- Integration of endocrine therapy for long‑term disease stabilization
Located at Virchowstrasse 10c, Singen, the Gastroenterology Oncology department of Onkologisch‑Gastroenterologische Schwerpunktpraxis Innere Medizin GbR conducts two investigator‑led trials to advance therapeutic options for patients with advanced breast cancer.
